GlassScriptPhysician profile
Laura Williams
NPI 1992891055
$3,328.55
in general payments reported to CMS, 2019-2025
25 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $432 · 2023: $490 · 2024: $734 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.40 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $434.55 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $241.03 | 2025 | Rezdiffra |
| Pfizer INC. | $196.18 | 2024-2025 | |
| Gilead Sciences, INC. | $135.00 | 2025 | Livdelzi |
| Astrazeneca Pharmaceuticals LP | $110.13 | 2021 | |
| Celgene Corporation | $109.36 | 2022-2024 | Zeposia |
| Melinta Therapeutics, LLC | $107.25 | 2025 | Kimyrsa |
| Takeda Pharmaceuticals U.S.A., INC. | $102.75 | 2021-2022 | |
| Janssen Biotech, INC. | $99.95 | 2021 | |
| Nestle Healthcare Nutrition INC. | $96.42 | 2021-2022 | |
| Medtronic, INC. | $86.89 | 2023-2024 | Interstim |
| Regeneron Healthcare Solutions, INC. | $64.61 | 2023 | Dupixent |
| Ardelyx, INC. | $51.70 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $42.49 | 2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $33.64 | 2023 | Axonics |
| Astellas Pharma US INC | $30.27 | 2024 | Veozah |
| Redhill Biopharma INC. | $29.12 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.53 | 2024 | Givlaari |
| Aimmune Therapeutics, INC. | $20.40 | 2024 | |
| Genentech USA, INC. | $19.03 | 2024 | Venclexta |
| Merck Sharp & Dohme LLC | $18.98 | 2024 | Dificid |
| Alkermes, INC. | $18.63 | 2024 | Lybalvi |
| Ferring Pharmaceuticals INC. | $13.03 | 2022 | |
| Amgen INC. | $11.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.